Finding patients on the road to cognitive decline
Nature Medicine
March 10, 2014
A blood profile, using ten metabolites, that can determine with 90% certainty whether a cognitively healthy elderly person will develop dementia symptoms in the next two to three years, is reported in a study published this week in Nature Medicine.
The challenge Alzheimer’s disease (AD) treatment is identifying aging individuals that are currently cognitively normal-but who may be more prone to develop dementia-before dementia onset, so that preventive therapy can be administered in a timely fashion.
Howard Federoff and colleagues found a biomarker panel of ten metabolites that are components of the cell membrane or their derivatives. This panel of biomarkers could represent early degenerative changes in neurons within the brain prior to dementia onset. As treatments aimed at individuals with Alzheimer’s disease are thought to be more likely to work if given at early stages of the disease, the findings could help with patient selection for clinical trials in dementia.
doi: 10.1038/nm.3466
Research highlights
-
Aug 12
Ageing: Mutations in the ageing human heart identifiedNature Aging
-
Aug 12
Palaeontology: T. rex and relatives traded big eyes for bigger bitesCommunications Biology
-
Aug 10
Epidemiology: Estimating the risk of SARS-related coronaviruses from bats in Southeast AsiaNature Communications
-
Aug 5
Microbiology: Single switch makes Escherichia coli beneficial insect partnerNature Microbiology
-
Aug 5
Conservation: More than half of unassessable species may be at risk of extinctionCommunications Biology
-
Aug 4
Physiology: Restoring cellular functions in pigs after deathNature